Frequently asked questions on surrogate endpoints in oncology via Bishal Gyawali et al.

Ash Paul, Medical Director of EoE Specialised Commissioning Group, shared a post on X about a recent paper by Bishal Gyawali et al. published in eClinical Medicine.

“Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward”

Authors: Abhenil Mittala, Myung Sun Kimb, Shenna Dunnc, Kristin Wright, Bishal Gyawali.

“Frequently asked questions on surrogate endpoints in oncology: opportunities, pitfalls, and the way forward via Bishal Gyawali et al.”

Source: Ash Paul/X

Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives.

Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.